Financhill
Sell
28

HEPA Quote, Financials, Valuation and Earnings

Last price:
$0.42
Seasonality move :
-14.52%
Day range:
$0.37 - $0.43
52-week range:
$0.25 - $70.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.60x
Volume:
2.2M
Avg. volume:
8.4M
1-year change:
-99.4%
Market cap:
$4.3M
Revenue:
--
EPS (TTM):
-$4.38

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HEPA
Hepion Pharmaceuticals
-- -- -- -- --
ARVN
Arvinas
$41.9M -$0.97 -54.66% -80.92% $22.36
FBIO
Fortress Biotech
$11.6M -$0.44 5.94% -96.07% $15.33
JANX
Janux Therapeutics
$650K -$0.39 -68.05% -30.48% $90.82
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
PFE
Pfizer
$14.1B $0.67 1.01% 5555.3% $29.25
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HEPA
Hepion Pharmaceuticals
$0.39 -- $4.3M -- $0.00 0% --
ARVN
Arvinas
$6.81 $22.36 $497.1M -- $0.00 0% 1.15x
FBIO
Fortress Biotech
$1.69 $15.33 $49.9M -- $0.00 0% 0.47x
JANX
Janux Therapeutics
$26.37 $90.82 $1.6B -- $0.00 0% 108.61x
NBY
NovaBay Pharmaceuticals
$0.57 $0.85 $3.3M -- $0.00 0% 0.15x
PFE
Pfizer
$22.97 $29.25 $130.6B 16.64x $0.43 7.36% 2.10x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HEPA
Hepion Pharmaceuticals
-- 5.387 -- --
ARVN
Arvinas
0.08% 3.030 0.1% 4.50x
FBIO
Fortress Biotech
71.75% 0.006 900.37% 0.99x
JANX
Janux Therapeutics
-- -1.142 -- 38.58x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
PFE
Pfizer
40.42% 0.423 42.46% 0.88x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HEPA
Hepion Pharmaceuticals
-- -$4.5M -- -- -- -$2.5M
ARVN
Arvinas
-- $71.4M -7.71% -7.72% 37.82% -$89.3M
FBIO
Fortress Biotech
$9.3M -$22.1M -94.06% -- -166.72% -$20.1M
JANX
Janux Therapeutics
-- -$29M -11.37% -11.37% -8164.47% -$16.8M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PFE
Pfizer
$10.9B $4.4B 5.05% 8.72% 25.08% $1.8B

Hepion Pharmaceuticals vs. Competitors

  • Which has Higher Returns HEPA or ARVN?

    Arvinas has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 43.91%. Hepion Pharmaceuticals's return on equity of -- beat Arvinas's return on equity of -7.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$0.72 --
    ARVN
    Arvinas
    -- $1.14 $660.6M
  • What do Analysts Say About HEPA or ARVN?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 380610.66%. On the other hand Arvinas has an analysts' consensus of $22.36 which suggests that it could grow by 228.36%. Given that Hepion Pharmaceuticals has higher upside potential than Arvinas, analysts believe Hepion Pharmaceuticals is more attractive than Arvinas.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    ARVN
    Arvinas
    9 8 0
  • Is HEPA or ARVN More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Arvinas has a beta of 2.215, suggesting its more volatile than the S&P 500 by 121.499%.

  • Which is a Better Dividend Stock HEPA or ARVN?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or ARVN?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Arvinas quarterly revenues of $188.8M. Hepion Pharmaceuticals's net income of -$4.9M is lower than Arvinas's net income of $82.9M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 1.15x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$4.9M
    ARVN
    Arvinas
    1.15x -- $188.8M $82.9M
  • Which has Higher Returns HEPA or FBIO?

    Fortress Biotech has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -87.96%. Hepion Pharmaceuticals's return on equity of -- beat Fortress Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$0.72 --
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
  • What do Analysts Say About HEPA or FBIO?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 380610.66%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 807.3%. Given that Hepion Pharmaceuticals has higher upside potential than Fortress Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Fortress Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    FBIO
    Fortress Biotech
    1 0 0
  • Is HEPA or FBIO More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.853, suggesting its more volatile than the S&P 500 by 85.291%.

  • Which is a Better Dividend Stock HEPA or FBIO?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or FBIO?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Hepion Pharmaceuticals's net income of -$4.9M is higher than Fortress Biotech's net income of -$12.9M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.47x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$4.9M
    FBIO
    Fortress Biotech
    0.47x -- $14.6M -$12.9M
  • Which has Higher Returns HEPA or JANX?

    Janux Therapeutics has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -6391.57%. Hepion Pharmaceuticals's return on equity of -- beat Janux Therapeutics's return on equity of -11.37%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$0.72 --
    JANX
    Janux Therapeutics
    -- -$0.36 $656.1M
  • What do Analysts Say About HEPA or JANX?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 380610.66%. On the other hand Janux Therapeutics has an analysts' consensus of $90.82 which suggests that it could grow by 244.4%. Given that Hepion Pharmaceuticals has higher upside potential than Janux Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Janux Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    JANX
    Janux Therapeutics
    11 1 0
  • Is HEPA or JANX More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HEPA or JANX?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or JANX?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Janux Therapeutics quarterly revenues of $439K. Hepion Pharmaceuticals's net income of -$4.9M is higher than Janux Therapeutics's net income of -$20.2M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 108.61x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$4.9M
    JANX
    Janux Therapeutics
    108.61x -- $439K -$20.2M
  • Which has Higher Returns HEPA or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -49.65%. Hepion Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$0.72 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About HEPA or NBY?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 380610.66%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.07%. Given that Hepion Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Hepion Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is HEPA or NBY More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock HEPA or NBY?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or NBY?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Hepion Pharmaceuticals's net income of -$4.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$4.9M
    NBY
    NovaBay Pharmaceuticals
    0.15x -- $2.4M -$1.2M
  • Which has Higher Returns HEPA or PFE?

    Pfizer has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 21.63%. Hepion Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$0.72 --
    PFE
    Pfizer
    79.26% $0.52 $151.9B
  • What do Analysts Say About HEPA or PFE?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 380610.66%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 27.33%. Given that Hepion Pharmaceuticals has higher upside potential than Pfizer, analysts believe Hepion Pharmaceuticals is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    PFE
    Pfizer
    6 15 1
  • Is HEPA or PFE More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

  • Which is a Better Dividend Stock HEPA or PFE?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.36% to investors and pays a quarterly dividend of $0.43 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or PFE?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Hepion Pharmaceuticals's net income of -$4.9M is lower than Pfizer's net income of $3B. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 2.10x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$4.9M
    PFE
    Pfizer
    2.10x 16.64x $13.7B $3B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
99
DAVE alert for May 9

Dave [DAVE] is up 6.07% over the past day.

Buy
52
QDEL alert for May 9

QuidelOrtho [QDEL] is down 0.55% over the past day.

Buy
61
TPC alert for May 9

Tutor Perini [TPC] is up 6.83% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock